Ata Mahmoodpoor1, Sahra Zahedi2, Arezou Pourakbar3, Hamed Hamishehkar4, Kamran Shadvar1, Parina Asgharian5, Farnaz Shahabi1, Hadi Hamishehkar6. 1. Department of Anesthesiology, Tabriz University of Medical Sciences, Tabriz, Iran. 2. Iranian Evidence Based Medicine Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran. 3. Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. 4. Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 5. Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. 6. Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. hamishehkar@gmail.com.
Abstract
BACKGROUND: Some physicians co-administer albumin with loop diuretics to overcome diuretic resistance in critically ill hypoalbuminemia patients, though previous studies have reported conflicting results on this matter. OBJECTIVE: The effects of adding albumin to furosemide to enhance its efficacy in critically ill hypoalbuminemia patients are evaluated. METHODS: This was a non-blinded randomized trial. 49 adult critically ill patients with hypoalbuminemia and generalized edema who receivedrandomly furosemide and furosemide/albumin complex were enrolled. The patients' urine was collected at intervals of 2, 4, 6 and 8 h after initiation of the furosemide treatment, and the urine output and urinary excretion of furosemide and sodium were measured. The urinary excretion of furosemide was considered an indicator of drug efficacy. RESULTS: The amount of sodium and furosemide excreted in urine showed no significant differences between the two groups; however, the mean of the urinary excretion of furosemide in the first 2 h after drug infusion was significantly higher (p = 0.03) in the furosemide/albumin group. No significant correlation between APACHE II scores and serum albumin levels and the urinary excretion of furosemide was seen. CONCLUSION: The results indicated that there is not statistically significant differences between groups with furosemide alone and combined with albumin in urinary furosemide excretion. It seems that adding albumin for furosemide pharmacotherapy regime is not recommended as an intervention to increase furosemide efficacy in critically ill hypoalbuminemia patients. TRIAL REGISTRATION: IRCT with the registration number IRCT201412132582N12 in 23 February 2015; https://en.irct.ir/trial/2356 Graphical abstract.
RCT Entities:
BACKGROUND: Some physicians co-administer albumin with loop diuretics to overcome diuretic resistance in critically ill hypoalbuminemiapatients, though previous studies have reported conflicting results on this matter. OBJECTIVE: The effects of adding albumin to furosemide to enhance its efficacy in critically ill hypoalbuminemiapatients are evaluated. METHODS: This was a non-blinded randomized trial. 49 adult critically illpatients with hypoalbuminemia and generalized edema who received randomly furosemide and furosemide/albumin complex were enrolled. The patients' urine was collected at intervals of 2, 4, 6 and 8 h after initiation of the furosemide treatment, and the urine output and urinary excretion of furosemide and sodium were measured. The urinary excretion of furosemide was considered an indicator of drug efficacy. RESULTS: The amount of sodium and furosemide excreted in urine showed no significant differences between the two groups; however, the mean of the urinary excretion of furosemide in the first 2 h after drug infusion was significantly higher (p = 0.03) in the furosemide/albumin group. No significant correlation between APACHE II scores and serum albumin levels and the urinary excretion of furosemide was seen. CONCLUSION: The results indicated that there is not statistically significant differences between groups with furosemide alone and combined with albumin in urinary furosemide excretion. It seems that adding albumin for furosemide pharmacotherapy regime is not recommended as an intervention to increase furosemide efficacy in critically ill hypoalbuminemiapatients. TRIAL REGISTRATION: IRCT with the registration number IRCT201412132582N12 in 23 February 2015; https://en.irct.ir/trial/2356 Graphical abstract.
Authors: Naga Chalasani; J Christopher Gorski; John C Horlander; Rebecca Craven; Helena Hoen; Juan Maya; D Craig Brater Journal: J Am Soc Nephrol Date: 2001-05 Impact factor: 10.121
Authors: Manu L N G Malbrain; Paul E Marik; Ine Witters; Colin Cordemans; Andrew W Kirkpatrick; Derek J Roberts; Niels Van Regenmortel Journal: Anaesthesiol Intensive Ther Date: 2014 Nov-Dec
Authors: Simon J W Oczkowski; Lisa Klotz; Ian Mazzetti; Fayez Alshamsi; Mei Lin Chen; Gary Foster; Maureen O Meade; Cindy Hamielec Journal: J Crit Care Date: 2018-07-19 Impact factor: 3.425
Authors: J R Voelker; D Cartwright-Brown; S Anderson; J Leinfelder; D A Sica; J P Kokko; D C Brater Journal: Kidney Int Date: 1987-10 Impact factor: 10.612
Authors: Saif Ali; Sharon Jung; Shuktika Nandkeolyar; Liset Stoletniy; Antoine Sakr; Frederik H Verbrugge; Anthony Hilliard; Dmitry Abramov Journal: Am J Cardiovasc Drugs Date: 2021-03-12 Impact factor: 3.571
Authors: Tao Han Lee; George Kuo; Chih-Hsiang Chang; Yen Ta Huang; Chieh Li Yen; Cheng-Chia Lee; Pei Chun Fan; Jia-Jin Chen Journal: PLoS One Date: 2021-12-01 Impact factor: 3.240